RE:RE:RE:Opposing Oncolytic Virus companies share pricesIf ONCY knew about its pending relationship with CGAR, as Matt Coffey keeps implying, then why didn't they get better funding arrangements?
Now Coffey says that ONCY " has entered into a preliminary collaboration with the Global Coalition for Adaptive Research (GCAR)."
"The purpose of the preliminary collaboration is to commence planning activities for the evaluation of pelareorep in the treatment of first-line metastatic pancreatic ductal adenocarcinoma (PDAC) as part of GCAR's anticipated master protocol for metastatic pancreatic cancer."